Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
/CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, announced that it has filed for...
Where Will Novavax Be in 1 Year?
We will know a lot more about the vaccine maker's long-term prospects in 12 months.
Is It Too Late to Buy Novavax Stock?
Shares of the vaccine maker are trading up 230% this year.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These pharma and biotech players could become long-term winners.
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?
Better Buy: Inovio Pharmaceuticals vs. Novavax
Both biotechs have been struggling for a while, but there might be some hope for them.
3 Things You Need to Know If You Buy Novavax Today
The vaccine maker's recovery story is looking brighter.
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
The biotech still hasn't lost momentum.
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths...